Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.840
-0.005 (-0.27%)
At close: Dec 20, 2024, 4:00 PM
1.850
+0.010 (0.54%)
After-hours: Dec 20, 2024, 7:41 PM EST
Inovio Pharmaceuticals Revenue
Inovio Pharmaceuticals had revenue of $203.41K in the twelve months ending September 30, 2024, down -76.18% year-over-year. In the year 2023, Inovio Pharmaceuticals had annual revenue of $832.01K, down -91.89%.
Revenue (ttm)
$203.41K
Revenue Growth
-76.18%
P/S Ratio
229.28
Revenue / Employee
$1,667
Employees
122
Market Cap
48.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 832.01K | -9.43M | -91.89% |
| Dec 31, 2022 | 10.26M | 8.49M | 478.23% |
| Dec 31, 2021 | 1.77M | -5.64M | -76.05% |
| Dec 31, 2020 | 7.41M | 3.30M | 80.24% |
| Dec 31, 2019 | 4.11M | -26.37M | -86.51% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xtant Medical Holdings | 113.86M |
| Fortress Biotech | 81.50M |
| Celularity | 48.20M |
| Cytosorbents | 37.74M |
| Shattuck Labs | 6.44M |
| Nutriband | 2.02M |
INO News
- 7 days ago - Gold Down Over 1%; Inovio Pharmaceuticals Shares Plummet - Benzinga
- 8 days ago - INOVIO Announces Pricing of $30 Million Public Offering - PRNewsWire
- 8 days ago - INOVIO Announces Proposed Public Offering - PRNewsWire
- 18 days ago - New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial - PRNewsWire
- 21 days ago - INOVIO Reports Inducement Grant Under Inducement Plan - PRNewsWire
- 5 weeks ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 5 weeks ago - Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights - PRNewsWire